On October 29, 2021, the FDA granted accelerated approval to asciminib (brand name Scemblix) for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors, and approved asciminib for adult patients with Philadelphia ...